Comparison of interleukin-17 level in leprosy and non-leprosy patients at Dr. Muhammad Hoesin Palembang general hospital

Siti sakdiah; Eddy mart salim; Zen hafy; Fifa argentina; Nova kurniati; Ya’kub rahadiyanto

Siti sakdiah Faculty of Medicine, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia.
Eddy mart salim Faculty of Medicine, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia.
Zen hafy Faculty of Medicine, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia.
Fifa argentina Faculty of Medicine, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia.
Nova kurniati Faculty of Medicine, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia.
Ya’kub rahadiyanto Faculty of Medicine, Universitas Sriwijaya, Palembang, Sumatera Selatan, Indonesia.

Abstract

Leprosy is a chronic disease caused by an infection of Mycobacterium Leprae. Leprosy has several clinical types that correlate with the immune response. The study was conducted to analyze the differences in serum IL-17 levels between leprosy and non-leprosy patient in RSUP Dr. Muhammad Hoesin Palembang. Research design is case control. The study was conducted at Dr. Muhammad Hoesin Palembang General Hospital and IL-17 Examination was conducted at the Molecular Biology Laboratory, Medical Faculty of Sriwijaya University Palembang from January to February 2019. The case and control groups samples were 40 lepers and 40 medical personnel and paramedics who work at Dr. Muhammad Hoesin Palembang General Hospital and also patients family. The parameters studied were IL-17 levels, respondent status, clinical type of leprosy and respondent characteristics. Serum IL-17 is measured with ELISA. The average age of leprosy patient is 35 years, and non-leprosy is 36.5 years. The frequency of men (27) is higher in lepers and women (24) in non-lepers. MB patient (36) is higher compared to PB patient (4), and there are 19, 10, and 7 respondent of BL, LL, and BB patient respectively. And also there are 2 respondent of TT and BT patient. The median score of IL-17 levels for non-lepers are 47.86 pg/ml and for lepers are 102.86 pg/ml with p <0.05. Conclusion, there are significant differences in IL-17 levels in lepers and non-lepers at Dr. Muhammad Hoesin Palembang General Hospital.

Keywords: Leprosy, Interleukin-17, Patients

Downloads

Download data is not yet available.

References

1. Abdallah, M; Emam, H; Attia, E; Hussein, J; Mohamed, N: Estimation of serum level of interleukin-17 and interleukin-4 in leprosy, towards more understanding of leprosy immunopathogenesis. Indian J Dermatol Venereol Leprol 2013; 7(9):772-6.
1. De Sousa, J.R; Sotto, MN; Quaresma, JA: Leprosy As a Complex Infection: Breakdown of the Th1 and Th2 Immune Paradigm in the Immunopathogenesis of the Disease. Front Immunol. 2017; 8(5):16-35.
2. Lavania, M., Jadhav, R. S., Chaitanya, V. S., Turankar, R., Selvasekhar, A., Das, L., & Sengupta, U. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India. Lepr Rev. 2019; 85(3): 77-85.
3. Attia, EAS; Abdallah, B; Khateeb, E; Saad, AA; Lotfi, RA; Abdallah, Shennawy, DE: Serum Th17 cytokines in leprosy:correlation with circulating CD4+CD25highFoxP3+ T-regs cells, as well as down regulatory cytokines. Arch Dermatol Res 2010; 5(8): 63-80.
4. Poovamma; Ashwini; Veeranna; Jayadev: Study of Serum Interleukin-17 and Interleukin-4 Levels in South Indian Leprosy Patients across Clinico-Histopathological Spectrum. Indian J Lepr. 2017; 8(9): 139-150.
5. De Oliveira Lorena bruna; Henrique P; Gama S.P; Branco C.A; Cipriano.LB; Magueta. B.E; De souza.M.L; Sarno.N.E; De oliviera F: Analysis of Cytokine Production in Household Contacts of Leprosy, Journal of Medica 2016; 6: 77-98.
6. Bhat; Prakash: Leprosy: An Overview of Pathophysiology. Hindawi Publishing Corporation Interdisciplinary Perspectives on Infectious Diseases. International journal of dermatology 2012; 4(12): 22-26.
7. Nalamada; Khan; Saher; Samreen; Ansari; Sarada: Incidence and Clinical Profile of Leprosy in a Tertiary Care Hospital in Hyderabad, Telangana. International Journal of Contemporary Medical Research 2018; 7(9): 67-80.
8. Fonseca; Simon; Cazzaniga; de Moura; de Almeida; Duthie; Reed; Jesus: The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy. Infectious Diseases of Poverty 2017; 5(9): 80-90.
9. Voorend; Post: A Systematic Review on the Epidemiological Data of Erythema Nodosum Leprosum, a Type 2 Leprosy Reaction. PLoS Negl Trop Dis. 2013; 9(2): 90-96.
10. Margoles; Rio; Paredes: Leprosy: a modern assessment of an ancient neglected disease. Bol Med Hosp Infant Mex, 2016; 68(2):110-116.
11. Bhat; Chaitra: Profile Of New Leprosy Cases Attending a South Indian Referral Hospital In 2011-2012, Hindawi Publishing Corporation 2013; 2(9): 78-90.
12. Gobena: The Immunopathology of Erythema Nodosum Leprosum. PhD thesis. London School of Hygiene & Tropical Medicine 2016; 8(9): 24-29.
13. Neto; Costa; Filho; Franco; de Lima; de Lorena; de Souza; Maja: TH17 cells, interleukin-17 and interferon- c in patients and households contacts of leprosy with multibacillary and paucibacillary forms before and after the start of chemotherapy treatment. Scandinavian journal of immunology. 2014; 45(9): 22-21.
14. Onishi; Gaffen: Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 8(7): 6-9.
15. Santos; de Oliveira; Cazzaniga; Varjao; dos Santos; Correia; Faria; Simon; Silvas; Dutra; Reed; Duthie; Almeida; de Jesus: Distinct Roles of Th17 and Th1 Cells in Inflammatory Responses Associated with the Presentation of Paucibacillary Leprosy and Leprosy Reactions Human Immunology. Journal of Immunology 2017; 6(9): 4-9.
16. Costa; Medeiros; Chaves; Lyon; Reis; Ribeiro; Oliveira; Rocha; Gomes: Cytokines as biomarkers to monitoring the impact of multidrug therapy in immune response of leprosy patients. Virginia Maria Barros de Lorena journal 2017; 8(9): 9-10.
17. Moubasher; Kamel; Zedan; Raheem: Cytokines In Leprosy, II. Effect of Treatment On Serum Cytokines In Leprosy. International Journal Of Dermatology.1998; 37:741-746
18. Degang; Nakamura; Akama; Ishido; Luo; Ishii; Suzuki: Leprosy as a model of immunity perspective. Future Microbiology. 2014; 8(6): 90-96.
19. Motta; Pereira; Tarquı´nio; Vieira; Miyake; Foss: Leprosy reactions: coinfections as a possible risk factor. CLINICS. 2012; 4(9): 90-98.
20. Neto; Costa; Filho; Franco; de Lima; de Lorena; de Souza; Maja: TH17 cells, interleukin-17 and interferon- c in patients and households contacts of leprosy with multibacillary and paucibacillary forms before and after the start of chemotherapy treatment. Journal of Dermatology 2014; 5(8): 65-80.
21. Neela; Devalraju; Pydi; Sunder; Adiraju; Singh: Mycobacterial r32-kDa antigen-specific T-cell responses correlate with successful treatment and a heightened anti-microbial response in human leprosy patients. International Immunology. 2016; 8(9): 66-80.
22. Klatt; Brenchley: TH 17 Cell Dyanics in HIV Infection, Journal of HIV 2010; 6(7): 90-98.
23. Passos; Malheiro; Naveca; De Souza.; De Barros; Cardoso; Da Grac; Cunha; Dos Santos; Villarouco; Silva; Fraporti; De Paula: Decreased RNA Expression Of Interleukin 17a In Skin Of Leprosy. Eur J Dermatol 2017; 22(4): 488-94.
24. Sadhu; Mitra: Emerging Concepts of Adaptive Immunity In Leprosy. Frontiers in Immunology 2018; 24(30): 31-32.